Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $89
Author: Benzinga Newsdesk | August 08, 2025 07:36am
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $77 to $89.